In light of recent evidence, a four-pillar strategy including RAS blockade, SGLT2 inhibition, nonsteroidal MRA, and GLP-1 RA is a well-founded approach for patients with T2D and albuminuric CKD. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.